166 related articles for article (PubMed ID: 11323158)
1. Anti-oestrogenic drugs and endometrial cancers.
White IN
Toxicol Lett; 2001 Mar; 120(1-3):21-9. PubMed ID: 11323158
[TBL] [Abstract][Full Text] [Related]
2. The tamoxifen dilemma.
White IN
Carcinogenesis; 1999 Jul; 20(7):1153-60. PubMed ID: 10383884
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen, screening and new oestrogen receptor modulators.
Neven P; Vergote I
Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):365-80. PubMed ID: 11476559
[TBL] [Abstract][Full Text] [Related]
4. Toxicity of antiestrogens.
Hirsimäki P; Aaltonen A; Mäntylä E
Breast J; 2002; 8(2):92-6. PubMed ID: 11896754
[TBL] [Abstract][Full Text] [Related]
5. The endometrial effects of SERMs.
Cano A; Hermenegildo C
Hum Reprod Update; 2000; 6(3):244-54. PubMed ID: 10874569
[TBL] [Abstract][Full Text] [Related]
6. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
Jordan VC; Gapstur S; Morrow M
J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
[TBL] [Abstract][Full Text] [Related]
7. Selective estrogen-receptor modulators in 2001.
O'Regan RM; Gradishar WJ
Oncology (Williston Park); 2001 Sep; 15(9):1177-85, 1189-90; discussion 1190-4. PubMed ID: 11589065
[TBL] [Abstract][Full Text] [Related]
8. The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk.
Williams-Brown MY; Salih SM; Xu X; Veenstra TD; Saeed M; Theiler SK; Diaz-Arrastia CR; Salama SA
J Steroid Biochem Mol Biol; 2011 Sep; 126(3-5):78-86. PubMed ID: 21600284
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen in postmenopausal women a safety perspective.
Robinson E; Kimmick GG; Muss HB
Drugs Aging; 1996 May; 8(5):329-37. PubMed ID: 8935395
[TBL] [Abstract][Full Text] [Related]
10. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
Pinkerton JV; Goldstein SR
Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
[TBL] [Abstract][Full Text] [Related]
11. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.
Bergman L; Beelen ML; Gallee MP; Hollema H; Benraadt J; van Leeuwen FE
Lancet; 2000 Sep; 356(9233):881-7. PubMed ID: 11036892
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen.
Brown K
Expert Opin Drug Saf; 2002 Sep; 1(3):253-67. PubMed ID: 12904141
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention of breast cancer by tamoxifen: risks and opportunities.
Smith LL; Brown K; Carthew P; Lim CK; Martin EA; Styles J; White IN
Crit Rev Toxicol; 2000 Sep; 30(5):571-94. PubMed ID: 11055836
[TBL] [Abstract][Full Text] [Related]
14. Antiestrogen therapy: uncertainties and risk assessment.
Smith LL; White IN
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):14-22. PubMed ID: 9556786
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor polymorphisms in tamoxifen-treated women with breast cancer.
Georgopoulos NA; Adonakis GL; Fotopoulos A; Koika V; Spinos N; Saltamavros A; Keramopoulos A; Koukouras D; Decavalas G; Kourounis GS
Gynecol Endocrinol; 2006 Apr; 22(4):185-9. PubMed ID: 16723304
[TBL] [Abstract][Full Text] [Related]
16. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
Jordan VC
J Med Chem; 2003 Mar; 46(7):1081-111. PubMed ID: 12646017
[No Abstract] [Full Text] [Related]
17. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis.
Wu H; Chen Y; Liang J; Shi B; Wu G; Zhang Y; Wang D; Li R; Yi X; Zhang H; Sun L; Shang Y
Nature; 2005 Dec; 438(7070):981-7. PubMed ID: 16355216
[TBL] [Abstract][Full Text] [Related]
18. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
19. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
O'Regan RM; Cisneros A; England GM; MacGregor JI; Muenzner HD; Assikis VJ; Bilimoria MM; Piette M; Dragan YP; Pitot HC; Chatterton R; Jordan VC
J Natl Cancer Inst; 1998 Oct; 90(20):1552-8. PubMed ID: 9790548
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells.
Sakamoto T; Eguchi H; Omoto Y; Ayabe T; Mori H; Hayashi S
Mol Cell Endocrinol; 2002 Jun; 192(1-2):93-104. PubMed ID: 12088871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
